We are live on ! Find out more
BLPH

Bellerophon Therapeutics, Inc.
BLPH

Delisted

BLPH was delisted on the 13th of October, 2023.

Back to rankings

15 hedge funds and large institutions have $8.35M invested in Bellerophon Therapeutics, Inc. in 2016 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

400% more repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 1

0% more funds holding

Funds holding: 15 → 15 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

8% less capital invested

Capital invested by funds: $9.09M → $8.35M (-$738K)

Holders
15
Holders Change
–
Holders Change %
0%
% of All Funds
0.37%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
5
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
NMVA
New Mountain Vantage Advisers
New York
+$5.3M
2
BC
Boxer Capital
California
+$1.72M
3
AC
Armistice Capital
New York
+$928K
4
SM
Sabby Management
Florida
+$733K
5
Renaissance Technologies
Renaissance Technologies
New York
+$170K

Top Sellers

Rank Fund Capital Flow
1
VKH
Virtu KCG Holdings
New York
-$19.3K
2
UBS Group
UBS Group
Switzerland
-$13K
3
Envestnet Asset Management
Envestnet Asset Management
Illinois
-$1K
4
TRCT
Tower Research Capital (TRC)
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
NMVA
1
New Mountain Vantage Advisers
New York
$5.5M +$5.3M +380,953 +118%
BC
2
Boxer Capital
California
$966K +$1.72M +123,810 New
Fidelity Investments
3
Fidelity Investments
Massachusetts
$633K – – –
AC
4
Armistice Capital
New York
$520K +$928K +66,667 New
SM
5
Sabby Management
Florida
$414K +$733K +52,657 New
Renaissance Technologies
6
Renaissance Technologies
New York
$124K +$170K +12,240 +331%
Alyeska Investment Group
7
Alyeska Investment Group
Illinois
$80K +$1.14K +82 +0.8%
LPL Financial
8
LPL Financial
California
$51K +$22.3K +1,600 +34%
Vanguard Group
9
Vanguard Group
Pennsylvania
$28K – – –
Citadel Advisors
10
Citadel Advisors
Florida
$15K +$10.2K +730 +64%
Creative Planning
11
Creative Planning
Kansas
$10K – – –
GA
12
Geneva Advisors
Illinois
$7K – – –
VKH
13
Virtu KCG Holdings
New York
$6K -$19.3K -1,386 -64%
UBS Group
14
UBS Group
Switzerland
– -$13K -618 Closed
Envestnet Asset Management
15
Envestnet Asset Management
Illinois
– -$1K -67 Closed
TRCT
16
Tower Research Capital (TRC)
New York
– -$1K -47 Closed

BLPH Hedge Fund Activity: Q4 2016 in Review

15 of the 4,001 institutional investors tracked by Wall St. Rank reported a position in Bellerophon Therapeutics, Inc. (BLPH) for Q4 2016, worth a combined $8.35M — down 8.1% from $9.09M a quarter earlier.

Fund positioning in BLPH was balanced in Q4 2016: 3 funds opened new positions, 3 closed out, 5 added to existing stakes and 1 trimmed.

The largest buyer was New Mountain Vantage Advisers, adding an estimated $5.3M. The largest seller was Virtu KCG Holdings, cutting an estimated $19.3K.

  • 15 institutional investors held Bellerophon Therapeutics, Inc. (BLPH) as of Q4 2016, unchanged from Q3 2016.
  • Funds reported $8.35M of Bellerophon Therapeutics, Inc. stock for Q4 2016, down 8.1% quarter-over-quarter.
  • 3 funds opened new Bellerophon Therapeutics, Inc. positions in Q4 2016 and 3 closed out, a net change of 0 holders.
  • The largest Bellerophon Therapeutics, Inc. buyer in Q4 2016 was New Mountain Vantage Advisers, an estimated $5.3M added.
  • The largest Bellerophon Therapeutics, Inc. seller in Q4 2016 was Virtu KCG Holdings, an estimated $19.3K sold.

Based on aggregated 13F filings for Q4 2016.